Search
Now showing items 11-20 of 31
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
(NATURE PORTFOLIO, 2020-04-01)
The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ...
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
(AMER SOC CLINICAL ONCOLOGY, 2020-08-10)
Bleeding complications in patients with squamous cell carcinoma of the head and neck.
(WILEY, 2021-06-12)
Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and ...
OX40 and 4-1BB delineate distinct immune profiles in sarcoma.
(TAYLOR & FRANCIS INC, 2022-12-31)
Systemic relapse after radiotherapy and surgery is the major cause of disease-related mortality in sarcoma patients. Combining radiotherapy and immunotherapy is under investigation as a means to improve response rates. ...
Methodology for the development of National Multidisciplinary Management Recommendations using a multi-stage meta-consensus initiative.
(BMC, 2022-07-11)
BACKGROUND: Methods for developing national recommendations vary widely. The successful adoption of new guidance into routine practice is dependent on buy-in from the clinicians delivering day-to-day patient care and must ...
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.
(eLIFE SCIENCES PUBL LTD, 2022-12-23)
BACKGROUND: Advanced head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to predict progression-free ...
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
(ELSEVIER, 2023-03-01)
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) ...
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
(ELSEVIER SCI LTD, 2023-09-01)
For the past 2 decades, cisplatin-based adjuvant chemoradiotherapy (CRT) has remained the standard of care for patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are at ...
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
(BMJ PUBLISHING GROUP, 2023-01-01)
BACKGROUND: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. METHODS: Patients had advanced ...
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-05-01)
PURPOSE: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring ...